Search

Displaying results 2071 - 2080 of 3020 in total
  1. Drug

    SW033291

    go.drugbank.com/drugs/DB32765
    Experimental

    [A275473, A275474] It has been found to increase prostaglandin E2 (PGE2) and is being investigated in accelerating of hematopoietic recovery and treating type 2 diabetes mellitus.[A275473, A275474]

  2. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. … The biosimilar is approved by the FDA and EMA as a safe, effective and affordable biological product and displays equivalent clinical efficacy, potency, and purity to the reference product [A7504].

    Products: EPORATIO 20000 I E /1ML, EPORATIO 1000 I E /0.5ML
  3. Drug

    αAβ–Gas6

    go.drugbank.com/drugs/DB17069
    Experimental

    αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal a...

  4. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.

  5. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    FDA approved on August 13, 2009.

  6. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.

  7. Drug

    Sulpiride

    go.drugbank.com/drugs/DB00391
    ApprovedWithdrawn

    [A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]

  8. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666]

  9. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY
  10. Drug

    Glucagon

    go.drugbank.com/drugs/DB00040
    ApprovedInvestigational

    [L7640,L7643] Glucagon was granted FDA approval on 14 November 1960.[L7631]